3:00 PM Abstract No. 273 Device-specific adverse event rates of retrievable inferior vena cava filters after 90 days: a systematic review and network meta-analysis

Abstract

We aim to estimate device-specific adverse events (AE) rates in retrievable inferior vena cava filter (rIVCF) and compare them between models. Despite a growing population with indwelling retrievable inferior vena cava filters, accurate estimates AE in rIVCF are lacking. In this systematic review and meta-analysis, we searched MEDLINE, CENTRAL, and ClinicalTrials.gov databases for studies describing AEs in rIVCF. Primary observational studies and clinical trials from January of 1998 to July 2018 that contained imaging follow-up after 90 days after device implantation were included. Individual rates of AEs for every device were pooled and compared by performing a network meta-analysis. We identified 2707 records from the initial search. We analyzed 41 studies, representing eight device types and 5977 filters. OptEase filters fractured significantly more frequently than other devices at 14.8% (95% CI 13.1-16.6). Celect filters penetrated adjacent structures significantly more frequently than other devices at 63.1% (95% CI 41.1-80.6). Recovery filters migrated significantly more frequently than other devices at 21.7% (95% CI 1.9-74.9). There were no significant differences in the rates of recurrent DVT, thrombus precluding retrieval, or obstruction among devices. Retrievable inferior vena cava filter AE rates are prevalent; significant differences in AE types and rates exist between different filter models. Further research is necessary to establish device safety profiles and clinical guidelines.